
    
      In the phase Ib portion, an escalated dose cohort is recruited to determine the maximum
      tolerated dose (MTD) and recommended phase II dose (RP2D) of anlotinib when given in
      combination with gemcitabine/cisplatin. The phase II portion is designed to characterize the
      efficacy and safety of the combination therapy in previous untreated patients with R/M-NPC.
    
  